135 related articles for article (PubMed ID: 29043987)
21. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G
Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879
[No Abstract] [Full Text] [Related]
22. Azacytidine induced localized Sweets syndrome in Myelodysplastic syndrome.
Dev T; Dudani P; Bhari N
Dermatol Ther; 2021 Mar; 34(2):e14754. PubMed ID: 33406304
[No Abstract] [Full Text] [Related]
23. Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.
Prebet T; Fenaux P; Vey N;
Haematologica; 2016 Oct; 101(10):e427-e428. PubMed ID: 27694503
[No Abstract] [Full Text] [Related]
24. Azacitine (vidaza) for myelodysplastic syndrome.
Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015
[TBL] [Abstract][Full Text] [Related]
25. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
26. Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.
Della Porta MG; Alessandrino EP
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1260-1. PubMed ID: 25020100
[No Abstract] [Full Text] [Related]
27. [Demethylating medication in myelodysplastic syndrome].
Manson ML; Derissen EJ; Wijermans PW; Schellens JH; Beijnen JH
Ned Tijdschr Geneeskd; 2012; 156(4):A3167. PubMed ID: 22278034
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
[No Abstract] [Full Text] [Related]
29. Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome.
Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Ueno D; Yamasaki T; Itoh T; Yokozaki H; Katayama Y
Eur J Haematol; 2014 Apr; 92(4):362-4. PubMed ID: 24341928
[No Abstract] [Full Text] [Related]
30. Azacitidine Use After Allogeneic Stem Cell Transplantation-Results From the Polish Adult Leukemia Group.
Drozd-Sokołowska J; Gil L; Waszczuk-Gajda A; Mądry K; Piekarska A; Dutka M; Basak GW; Karakulska-Prystupiuk E; Dwilewicz-Trojaczek J
Transplant Proc; 2016 Jun; 48(5):1802-5. PubMed ID: 27496495
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.
Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Leukemia; 2015 Dec; 29(12):2449-51. PubMed ID: 26369829
[No Abstract] [Full Text] [Related]
32. Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.
Itzykson R; Thépot S; Quesnel B; Dreyfus F; Recher C; Wattel E; Gardin C; Adès L; Fenaux P
Blood; 2012 Jun; 119(25):6172-3. PubMed ID: 22730526
[No Abstract] [Full Text] [Related]
33. Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center.
Kim SY; Cho SG; Cho BS; Kim MS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Kim DW; Lee JW; Min WS
Bone Marrow Transplant; 2010 Aug; 45(8):1375-6. PubMed ID: 20023706
[No Abstract] [Full Text] [Related]
34. Transplantation for MDS in the elderly: more evidence, or more bias?
Cutler C
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1320-1. PubMed ID: 22750646
[No Abstract] [Full Text] [Related]
35. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Pierce S; Wierda W; Bueso-Ramos C; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G
Lancet Haematol; 2015 Jan; 2(1):e12-20. PubMed ID: 26687423
[TBL] [Abstract][Full Text] [Related]
36. Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Karakulska-Prystupiuk E; Drozd-Sokołowska J; Waszczuk-Gajda A; Stefaniak A; Dwilewicz-Trojaczek J; Kulikowska A; Chmarzyńska-Mróz E; Basak G; Paluszewska M; Boguradzki P; Jędrzejczak W
Transplant Proc; 2018 Sep; 50(7):2212-2217. PubMed ID: 30177138
[TBL] [Abstract][Full Text] [Related]
37. Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine.
Daitoku S; Aoyagi T; Takao S; Tada S; Kuroiwa M
Intern Med; 2018 Oct; 57(20):2995-2999. PubMed ID: 29780114
[TBL] [Abstract][Full Text] [Related]
38. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
39. The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.
Lamarque M; Raynaud S; Itzykson R; Thepot S; Quesnel B; Dreyfus F; Rauzy OB; Turlure P; Vey N; Recher C; Dartigeas C; Legros L; Delaunay J; Visanica S; Stamatoullas A; Fenaux P; Adès L
Blood; 2012 Dec; 120(25):5084-5. PubMed ID: 23243156
[No Abstract] [Full Text] [Related]
40. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
